gefitinib has been researched along with Leiomyosarcoma, Epithelioid in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Biffoni, M; Canzonieri, V; Colarossi, C; D'Andrea, V; De Antoni, E; De Maria, R; Di Matteo, P; Eramo, A; Fecchi, K; Memeo, L; Salvati, V; Sette, G; Signore, M | 1 |
1 other study(ies) available for gefitinib and Leiomyosarcoma, Epithelioid
Article | Year |
---|---|
EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential.
Topics: Animals; Cell Differentiation; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Leiomyosarcoma; Mice; Neoplasm Grading; Neoplastic Stem Cells; Phenotype; Phosphoproteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Vincristine; Xenograft Model Antitumor Assays | 2012 |